Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time-restricted versus standard immunosuppression to prevent severe GVHD after allogeneic stem cell transplantation
NL-OMON28315Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate sodium in graft-versus-host disease (GVHD) (2 arms), sponsored by HOVON. Primary endpoint: Proportion of patients with non-severe GVHD within day 180. Started Mar 2010; status: recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NL-OMON28315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28315.